Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib

Royalty Pharma (RPRX) announced that it has acquired a pre-existing royalty interest in Nuvalent’s (NUVL) neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors. Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer, NSCLC, and zidesamtinib is in development for ROS1 mutation-positive NSCLC. Both therapies are designed to deliver a best-in-class combination of efficacy and tolerability. Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The expected royalty duration for both therapies extends through approximately 2041 to 2042.